Pharmacokinetics of isolated hepatic perfusion with high dose tumor necrosis factor in rat model

Anticancer Research

Volumn 20, Issue 1 C, 2000, Pages 619-622

  Nakamoto, Takeru ^a,b   Inagawa, Hiroyuki ^a   Takagi, Koichi ^a   Tashiro, Kazuhiro ^a   Yoshimura, Hiroshi ^a   Nishizawa, Takashi ^a   Honda, Teruko ^a   Kanou, Junko ^a   Muto, Yoshihiro ^b   Amm, Eggermont ^c   Soma, Gen Ichiro ^a  

^a TAKANO HOSPITAL   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c NONE

Author keywords

Isolation; Liver; Metastasis; Perfusion; TNF SAM2

Indexed keywords

RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CELL STRAIN L 929; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; ISOLATED LIVER; LIVER METASTASIS; LIVER PERFUSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SWINE; SYSTEMIC CIRCULATION;

ANIMALS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; LIVER; MALE; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 19244368766     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Eggermont AM, Schraffordt Koops H, Liénard D, et al: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin. Oncol 14: 2653-2665, 1996.
2. Lejeune FJ, Liénard D, Eggermont AM, et al: Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. J Infus Chemother 5: 73-81, 1995.
3. Fraker DL, Alexander HR, Andrich M, et al: Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1: 122, 1995.
4. Gutman M, Inbar M, Lev-Shlush D, et al: High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 79: 1129-1137, 1997 .
5. van Ijken MG, de Bruijn E, de Boeck G, et al: Isolated Hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: A pharmacokinetic study in pigs. Ann Surg 228: 762-770, 1998.
6. Marinelli A, van de Velde CJ, Kuppen PJ, et al: A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. Br J Cancer 62: 891-896, 1990.
7. Marinelli A, van Dierendonck JH, van Brakel GM, et al: Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion. Br J Cancer 64: 1069-1075, 1991 .
8. Del Mastro L, Venturini M, Giannessi PG, et al: Intraperitoneal infusion of recombinant human tumor necrosis factor and mitoxantrone in neoplastic ascites: a feasibility study. Anticancer Res 15: 2207-2212, 1995 .
9. Tomita A, Fuchino Y, Otsuka K, et al: Clinical effects of exogenous/ endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res 18: 3937-3939, 1998 .
10. Gabrilove JL, Starnes MF, Begas A, et al: Phase I studies of rTNF-α in patients with advanced cancer. Immunobiology 175: 12-13, 1987.
11. Taguchi T: Clinical studies of recombinant human tumor necrosis factor (rHu-TNF). Immunobiology 175: 37-38, 1987.
12. Soma G-I, Tsuji Y, Tanabe Y, et al: Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells. J Biol Resp Modif 7: 587-595, 1988.
13. Gatanaga T, Noguchi K, Tanabe Y, et al: Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-α in vivo. J Biol Resp Modif 8: 278-286, 1989.
14. Ruff MR, Gifford GE: Purification and physicochcmical characterization of rabbit tumor necrosis factor. J Immunol 125: 1671-1677, 1980.
15. Gatanaga T, Takahashi T, Yamazaki M, et al. Combination antitumor therapy with rabbit tumor necrosis factor and chemo- and immunotherapeutic agents against murine tumors. Jpn J Cancer Res 76: 631-636, 1985.
16. Treffers HP: The linear representation of dosage-response curves in microbial-antibiotic assay. J Bacteriol 72: 108-114, 1956.
17. de Brauw LM, van de Velde CJ, Tjaden UR, et al: In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue. J Surg Res 44: 137-145, 1988.
18. Sigurdson ER, Ridge JA, Kemeny N, et al: Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 5: 1836-1840, 1987.
19. Boddie AW Jr, Booker L, Mullins JD, et al: Hepatic hyperthermia by total isolation and regional perfusion in vivo. J Surg Res 26: 447-457, 1979.
20. Alexander HR, Barlett D, Libutti S, et al: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16: 1479-1489, 1998.
21. Noguchi K, Bos E, Kanou J, et al: Predominance of rTNF-SAM2 with higher therapeutic index than conventional TNF-α is ascribed to the style of oligomer. (Abst) Eur Cytokine Netw 5: 183, 1994.
22. Borel Rinkes IH, de Vries MR, Jonker AM, et al: Isolated hepatic perfusion in the pig with TNF-αlpha with and without melphalan. Br J Cancer 75: 1447-14453, 1997.